Adaptive Biotechnologies Corporation
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$13.63
Price+0.67%
$0.09
1Y
Price
Market Cap
$2.181b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-20.3%
EBITDA Margin-28.3%
Net Profit Margin-14.6%
Free Cash Flow Margin-20.3%
EBITDA Margin-28.3%
Net Profit Margin-14.6%
Free Cash Flow MarginRevenue
$295.407m
+6.7%
1y CAGR+22.2%
3y CAGR+14.6%
5y CAGREarnings
-$49.680m
+16.5%
1y CAGR+36.1%
3y CAGR+24.0%
5y CAGREPS
-$0.33
+15.4%
1y CAGR+36.7%
3y CAGR+13.5%
5y CAGRBook Value
$224.241m
$505.943m
Assets$281.702m
Liabilities$208.181m
DebtDebt to Assets
41.2%
-9.4x
Debt to EBITDAFree Cash Flow
-$29.535m
+39.7%
1y CAGR+43.7%
3y CAGR+36.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company